Literature DB >> 8980020

Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions.

G M Pasinetti1, G Tocco, S Sakhi, W D Musleh, M G DeSimoni, P Mascarucci, S Schreiber, M Baudry, C E Finch.   

Abstract

Possible roles of the complement (C) system in the normal and injured brain were explored with inbred mice that carried a frameshift mutation in the C5 gene. A congenic pair was used: the C5-sufficient (C5+) B10.D2/nSnJ strain with the functional allele (Hc1) from the C57BL/10J donor strain was compared with the C5-deficient (C5-) B10.D2/oSnJ with the Hc0 allele from the C5-deficient DBA/2J donor strain. In response to the excitotoxin kainic acid (KA), C5- mice had more hippocampal pyramidal neuron death and greater induction of astrocyte mRNAs (GFAP, apoE, apoJ). In primary astrocyte cultures from unlesioned mice, an inflammatory stimulus (LPS) caused greater production of IL-6 and TNF production in C5- mice. These enhanced responses to KA and LPS suggest that hereditary C5 deficits modify responses to neurodegenerative stimuli of neurons and astrocytes. Moreover, unlesioned C5- mice had smaller input-output slopes for the NMDA component of the EPSP amplitude, but enhanced the Ca(+2)-dependent AMPA binding. Thus, C5 deficits also modify basal properties of glutamatergic neurotransmission that pertain to synaptic plasticity. These findings are also discussed in relation to roles of the C-system in Alzheimer disease (AD). C5 deficiencies may also be considered in the choice of strains as transgene hosts and for genetic analysis of normal and pathological brain functions. In recent transgenic studies for AD, C5- hosts showed greater neurodegeneration, consistent with the present data. These pleiotropic associations of C5 deficiency indicate roles for the C-system in neurodegeneration, but also in normal neural functions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980020     DOI: 10.1006/nbdi.1996.0020

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  22 in total

Review 1.  Complement in central nervous system inflammation.

Authors:  Scott R Barnum
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Complement in neuroprotection and neurodegeneration.

Authors:  Vijay Yanamadala; Robert M Friedlander
Journal:  Trends Mol Med       Date:  2010-01-28       Impact factor: 11.951

Review 3.  [The relevance of the inflammatory response in the injured brain].

Authors:  O I Schmidt; I Leinhase; E Hasenboehler; S J Morgan; P F Stahel
Journal:  Orthopade       Date:  2007-03       Impact factor: 1.087

4.  Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.

Authors:  Hee Young Hwang; Marcus R Duvall; Stephen Tomlinson; Robert J Boackle
Journal:  Mol Immunol       Date:  2008-03-03       Impact factor: 4.407

Review 5.  The complement cascade as a therapeutic target in intracerebral hemorrhage.

Authors:  Andrew F Ducruet; Brad E Zacharia; Zachary L Hickman; Bartosz T Grobelny; Mason L Yeh; Sergey A Sosunov; E Sander Connolly
Journal:  Exp Neurol       Date:  2009-07-24       Impact factor: 5.330

6.  Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease.

Authors:  Maria I Fonseca; Rahasson R Ager; Shu-Hui Chu; Ozkan Yazan; Sam D Sanderson; Frank M LaFerla; Stephen M Taylor; Trent M Woodruff; Andrea J Tenner
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

Review 7.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

8.  Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

Authors:  Marcel Maier; Ying Peng; Liying Jiang; Timothy J Seabrook; Michael C Carroll; Cynthia A Lemere
Journal:  J Neurosci       Date:  2008-06-18       Impact factor: 6.167

9.  Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis.

Authors:  Susanna H Weerth; Horea Rus; Moon L Shin; Cedric S Raine
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury.

Authors:  Manuel D Galvan; Sabina Luchetti; Adrian M Burgos; Hal X Nguyen; Mitra J Hooshmand; Frank P T Hamers; Aileen J Anderson
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.